Overview

SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

Status:
Completed

Trial end date:
2020-11-17

Target enrollment:

Participant gender:

Summary

This is a multi-institution, single-arm phase II study to determine the safety and efficacy of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma(with a clear-cell component and at least 1 measurable metastatic lesion that is not being irradiated).

Phase:

Phase 2

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab